Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
DSIP Regulatory Status As of June 2026, DSIP is not FDA-approved for any human indication
In two Phase 2 clinical trials covering stasis and pressure ulcers, TB4 accelerated complete wound closure by almost a month in patients who achieved full healing representing one of the most substantial healing acceleration outcomes observed for a peptide compound in a controlled clinical investigation
\n\n Related Reading: For a comprehensive overview of BPC-157 research, mechanisms, UK sourcing, and safety data, see our BPC-157 UK: Complete Research Guide (2026).
It was named for its ability to increase slow-wave (delta) sleep in early animal studies
Research on AHK-Cu has focused on several areas of interest
The Month 2 dose increase is data-driven, not arbitrary
US$ 25.18
US$ 23.30
US$ 21.35
